Selexipag in patients with pulmonary arterial hypertension associated with connective tissue disease (PAH‐CTD): Real‐world experience from EXPOSURE

Abstract Selexipag is indicated for the treatment of pulmonary arterial hypertension (PAH), including PAH associated with connective tissue disease (CTD), and further insights into the management of selexipag‐treated PAH‐CTD patients in clinical settings are needed. These analyses of the ongoing, mu...

Full description

Bibliographic Details

Published in:	Pulmonary Circulation
Main Authors:	Sean Gaine, Pilar Escribano‐Subias, Audrey Muller, Catarina C. Fernandes, Martina Fontana, Tatiana Remenova, Stefan Söderberg, Tobias J. Lange
Format:	Article
Language:	English
Published:	Wiley 2024-07-01
Subjects:	real‐world evidence registry scleroderma survival treatment patterns
Online Access:	https://doi.org/10.1002/pul2.12403